NANOS 2022 Poster 293: Lonigutamab Phase 1a Single-Ascending Dose Summary, March 2023
Download
About ACELYRIN
ACELYRIN, INC. is a Los Angeles area-based late-stage clinical biopharmaceutical company – with additional operations in the San Francisco Bay area – focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of promising drug candidates.
Learn more